Patient outcomes. Kaplan-Meier plots of DOR in patients with CR or PR per Lugano criteria by investigator assessment (A); DOCR in patients with CR per Lugano criteria by investigator assessment (B); PFS by investigator assessment (C); and OS overall and in patients with POD24, primary refractory disease (disease refractory to 1L antilymphoma therapy), and double-refractory disease (disease refractory to both anti-CD20 and an alkylating agent) (D). Kaplan-Meier estimates are shown. NR, not reached.